Dasatinib, large granular lymphocytosis, and pleural effusion: Useful or adverse effect?

Critical Reviews in Oncology/Hematology

Volumn 89, Issue 2, 2014, Pages 242-247

  Paydas, Semra ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Chronic myeloid leukemia; Dasatinib; Immune regulation; Large granular lymphocytosis; Pleural effusion; Response

Indexed keywords

DASATINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; CYTOTOXICITY; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; HEART DISEASE; HUMAN; HYPERTENSION; IMMUNOREGULATION; LARGE GRANULAR LYMPHOCYTOSIS; LYMPHOCYTOSIS; PATHOGENESIS; PLEURA EFFUSION; PREVALENCE; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

CHRONIC MYELOID LEUKEMIA; DASATINIB; IMMUNE REGULATION; LARGE GRANULAR LYMPHOCYTOSIS; PLEURAL EFFUSION; RESPONSE;

ANIMALS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYMPHOCYTOSIS; PLEURAL EFFUSION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 84892527099     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.10.005     Document Type: Review

References (44)

1. Apperley J.F., Cortes J.E., Kim D.W., et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol 2009, 27:3472-3479.
2. Hantschel O., Rix U., Schmidt U., et al. The Btk tyrosine kinase is a majör target of the Bcr-Abl inhibitör dasatinib. Proc Natl Acad Sci USA 2007, 104:13283-13288.
3. Rix U., Hantschel O., Dürnberger G., et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007, 110:4055-4063.
4. Bantscheff M., Eberhard D., Abraham Y., et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007, 25:1035-1044.
5. Kreutzman A., Jaatinen T., Greco D., et al. Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia. Exper Hematol 2012, 40:906-913.
6. Savani B.N., Mielke S., Adams S., et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 2007, 21:21452152.
7. Barrett A.J., Savani B.N. Does chemotherapy modify the immune surveillance of hematological malignancies. Leukemia 2009, 23:53-58.
8. Blake S., Hughes T.P., Mayrhofer G., Lyons A.B. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol 2008, 127:330-339.
9. Fei F., Yu Y., Schmitt A., et al. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Exp Hematol 2008, 36:1297-1308.
10. Schade A.E., Schieven G.L., Townsend R., et al. a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008, 111:1366-1377.
11. Nagata Y., Ohashi K., Fukuda S., Kamata N., Akiyama H., Sakamaki H. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int J Hematol 2010, 91:799-807.
12. Zarbock A., Ley K. Protein tyrosine kinases in neutrophil activation and recruitment. Arch Biochem Biophys 2011, 510:112-119.
13. Imagawa J., Tanaka H., Matsumoto K., Morito K., Harada Y., Harada H. A sharp fluctuation in peripheral blood cells shortly after dasatinib administration. In J Hematol 2012, 96:194-199.
14. Lavallade H., Punnialingam S., Milojkovic D., et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 2008, 141:734-747.
15. Porkka K., Khoury J., Paquette R.L., et al. Dasatinib 100mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukaemia in chronic phase and efficacy is uneffected in patients who develop pleural effusion. Cancer 2010, 116:377-386.
16. Mustjoki S., Ekblom M., Arstila T.P., et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009, 23:1398-1405.
17. Bergeron A., Rea D., Levy V., et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukaemia. Am J Resp Crit Care Med 2007, 176:814-818.
18. Tanaka H., Nakashima S., Usuda M. Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myeloid leukaemia patients. In J Hematol 2012, 10.1007/s12185-012-1132-8.
19. Kim D.H., Kamel-Reid S., Chang H., et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 2009, 94:135-139.
20. Lee S.J., Jung C.W., Kim D.Y., et al. Retrospective multicenter study on the development on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukaemia. Am J Hematol 2011, 86:346-350.
21. Kreutzman A., Juvonen V., Kairisto V., et al. Mono/oligoclonla T and NK cells are common in chronic myeloid leukaemia patients and expand during dasatinib therapy. Blood 2010, 116:772-782.
22. Kreutzman A., Ladell K., Koechel C., et al. Expansion of highly differentiated CD8+ T cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 2011, 25:1587-1597.
23. Valent J.N., Schiffer C.A. Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML). Leuk Res 2011, 35:e1-e3.
24. Hoshino T., Tahara K., Miyawaki K., et al. Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib. Rinsho Ketsueki. 2010, 51:181-188.
25. Cervantes F., Pierson B.A., McGlave P.B., Verfaillie C.M., Miller J.S. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood 1996, 87:2476-2485.
26. Silla L.M., Pincus S.M., Locker J.D., et al. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukemia and their role in the in vitro disappearance of BCR/ABL-positive targets. Br J Haematol 1996, 93:375-385.
27. Lowin-kropf B., Schneider P., Held W. A role for the src family kinase Fyn in NK cell activation and the formation of the repertoire of Ly49 receptors. Eur J Immunol 2002, 32:773-782.
28. Bloch-Queyrat C., Fondaneche M.C., Chen R., et al. Regulation of natural cytotoxicity by the adaptor SAP and the Src-related kinase Fyn. J Exp Med 2005, 202:181-192.
29. Pignata C., Prasad K.V., Hallek M., et al. Phosphorylation of src family tyrosine kinase following interleukin-12 activation of human natural killer cells. Cell Immunol 1995, 165:211-216.
30. Ting T., Dick C.J., Schoon R., Karnitz L.M., Abraham R.T., Leibson P.J. Interaction between lck and syk family tyrosine kinases in Fc gamma receptor-initiated activation of natural killer cells. J Biol Chem 1995, 270:16415-16421.
31. Gadue P., Morton N., Stein P.L. The Src family tyrosine kinase Fyn regulates natural killer T cell development. J Exp Med 1999, 190:1189-1196.
32. Weichsel R., Dix C., Wooldridge L., et al. Profound inhibition of antigen- specific T-cell effector functions by dasatinib. Clin Cancer Res 2008, 14:2484-2491.
33. Rohon P., Porkka K., Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 2010, 85:387-398.
34. Powers J.J., Dubovsky J.A., Epling-Burnette P.K., et al. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma 2011, 52:668-679.
35. Molldrem J.J., Lee P.P., Wang C., et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000, 6:1018-1023.
36. Sconocchia G., Lau M., Provenzano M., et al. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target cell interactions. Blood 2005, 106:3666-3672.
37. Bergeron A., Rea D., Levy V., et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia. Am J Crit Care Med 2007, 176:814-818.
38. Khoury H.J., Guilhot F., Hughes T.P., Kim D.W., Cortes J.E. Dasatinib treatment for Philadelphia chromosome positive leukemias. Cancer 2009, 115:1381-1394.
39. Shah N.P., Kim D.W., Kantarjian H.M., et al. Dasatinib 50mg or 70mg BID compared to 100mg or 140mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: one-year results of CA180034 (abs). J Clin Oncol 2008, 26:3204-3212.
40. Quintâs-Cardama A., Kantarjian H., O'brien S., et al. Pleural effusion in patients with chronic myeloid leukemia treated ith dasatinib after imatinib failure. J Clin Oncol 2007, 25:3908-3914.
41. de Lavallade H., Punnialingam S., Milojkovic D., et al. Pleural effusions in patients with chronic myeloid leukemia treated with dasatinib may have an immun-mediated pathogenesis. Br J Haematol 2008, 141:745-747.
42. Deininger M.W., O'Brien S.G., Ford J.M., Druker B.J. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003, 21:1637-1647.
43. Pugh-Bernard A.E., Cambier J.C. B cell receptor signaling in human systemic lupus erythematosus. Curr Opin Rheumatol 2006, 18:451-455.
44. Jury E.C., Kabouridis P.S., Abba A., Mageed R.A., Isenberg D.A. Increased ubiquination and reduced expression of LCK in T lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 2003, 48:1343-1354.